Safety and therapeutic efficacy of artesunate suppositories for treatment of malaria in children in Papua New Guinea

Pediatr Infect Dis J. 2003 Mar;22(3):251-6. doi: 10.1097/01.inf.0000054826.80221.75.

Abstract

Background: Although suppositories of artemisinin derivatives may be a valuable option for treatment of malaria in children when circumstances prevent oral and parenteral therapy, few confirmatory data have been published.

Methods: We assessed the safety and efficacy of rectal artesunate in 47 children ages 5 to 10 years with uncomplicated malaria acquired in a hyperendemic area of Papua New Guinea. Thirty were symptomatic and had Plasmodium falciparum parasitemia >2000/microl (Group 1), 12 had and either a parasitemia <2000/microl or minimal/no symptoms (Group 2) and 5 had Plasmodium vivax (Group 3). Each child received rectal artesunate 10 to 15 mg/kg at 0 and 12 h. After monitoring for 24 h, chloroquine plus sulfadoxine/pyrimethamine was given, and the patient discharged.

Results: Artesunate suppositories were well-tolerated. After 24 h only one child (from Group 1) had persistent parasitemia, and only one (from Group 3) had not defervesced. These two children received intramuscular quinine and recovered uneventfully. Three Group 2 children redeveloped fever and tachycardia at 24 h, but each responded to simple supportive measures and remained aparasitemic.

Conclusions: Intrarectal artesunate is safe, effective initial treatment for uncomplicated malaria in children. A transient fever spike can sometimes occur after parasite clearance. We recommend that children with uncomplicated malaria receive two doses of > or =10 mg/kg rectal artesunate within the first 24 h.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antimalarials / administration & dosage*
  • Artemisinins / administration & dosage*
  • Artesunate
  • Child
  • Child, Preschool
  • Cohort Studies
  • Developing Countries
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Endemic Diseases / statistics & numerical data*
  • Female
  • Follow-Up Studies
  • Humans
  • Malaria, Falciparum / diagnosis
  • Malaria, Falciparum / drug therapy*
  • Malaria, Falciparum / epidemiology
  • Malaria, Vivax / diagnosis
  • Malaria, Vivax / drug therapy*
  • Malaria, Vivax / epidemiology
  • Male
  • Monitoring, Physiologic
  • Papua New Guinea / epidemiology
  • Plasmodium falciparum / drug effects*
  • Plasmodium falciparum / isolation & purification
  • Plasmodium vivax / drug effects*
  • Plasmodium vivax / isolation & purification
  • Prospective Studies
  • Sesquiterpenes / administration & dosage*
  • Sulfadoxine / administration & dosage
  • Suppositories
  • Treatment Outcome

Substances

  • Antimalarials
  • Artemisinins
  • Sesquiterpenes
  • Suppositories
  • Artesunate
  • Sulfadoxine